First Cancer Vaccine Reduces Melanoma Recurrence and Death Risk
The world's first cancer vaccine has shown promising results in reducing the risk of melanoma recurrence and death. Clinical trials demonstrated up to a 42% decrease in these risks, marking a significant advancement in cancer treatment. The vaccine, developed to target skin cancer, has generated positive market reactions, including a rise in Evaxion's shares.
NewsBytes·




